About Maia Biotechnology Inc
- Industry: Biotechnology
- Exchange: NYSE MKT LLC
- Country: US
- Website: https://maiabiotech.com/
Frequently Asked Questions
What is the 52-week range for MAIA?
The 52-week high is $3.19 and the 52-week low is $0.87.
What is the P/E ratio for MAIA?
The P/E ratio data is currently unavailable.
What is the dividend yield for MAIA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -211.15%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 23.85.
Analyst Recommendation Trends
Wall Street analyst consensus for MAIA over the last few months:
Latest MAIA News
MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement
PRELIMINARY PROSPECTUSSubject to completion, dated September 25, 2026 751,879 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the "Selling Stockholder") is offering
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for
MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer
THIO-104 advances toward key 2027 interim survival analysisCHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC CHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that enro
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that
MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million NIH grant to MAIA
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10
MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share
Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr.
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleoside
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Theagene Jean-Manasse | +32,012 | - | - |
| 2026-09-30 | Smith Stan | +38,871 | - | - |
| 2026-09-30 | Luput Cristian | +33,536 | - | - |
| 2026-09-30 | Louie Ngar Yee | +39,634 | - | - |
| 2026-09-30 | Guerrero Ramiro | +32,012 | - | - |
| 2026-09-30 | CHAOUKI STEVEN M | +32,774 | - | - |
| 2026-09-14 | Vitoc Vlad | +73,000 | $1.37 | $100,010 |
| 2026-09-10 | Guerrero Ramiro | +37,595 | $1.3171 | $49,516 |
| 2026-08-28 | Guerrero Ramiro | +46,620 | $1.35 | $62,937 |
| 2026-08-27 | Guerrero Ramiro | +78,239 | $1.39 | $108,752 |
| 2026-08-26 | Guerrero Ramiro | +8,931 | $1.39 | $12,414 |
| 2026-08-24 | Guerrero Ramiro | +1,794 | $1.33 | $2,386 |
| 2026-08-20 | Guerrero Ramiro | +11,899 | $1.37 | $16,302 |
| 2026-06-30 | Guerrero Ramiro | +26,355 | - | - |
| 2026-06-30 | Louie Ngar Yee | +32,630 | - | - |
| 2026-06-30 | Luput Cristian | +27,610 | - | - |
| 2026-06-30 | Smith Stan | +32,003 | - | - |
| 2026-06-30 | Theagene Jean-Manasse | +26,355 | - | - |
| 2026-06-30 | CHAOUKI STEVEN M | +26,982 | - | - |
| 2026-06-01 | Vitoc Vlad | +72,700 | $1.3877 | $100,886 |
| 2026-06-01 | Smith Stan | +75,000 | $1.336 | $100,200 |
| 2026-06-01 | Gryaznov Sergei | +2,000 | $1.345 | $2,690 |
| 2026-05-29 | Vitoc Vlad | +800,000 | - | - |
| 2026-05-29 | Gryaznov Sergei | +400,000 | - | - |
| 2026-05-29 | Himmelreich Jeffrey C | +60,000 | - | - |
| 2026-04-10 | Vitoc Vlad | +800,000 | - | - |
| 2026-04-10 | Gryaznov Sergei | +400,000 | - | - |
| 2026-04-10 | Himmelreich Jeffrey C | +30,000 | - | - |
| 2026-03-31 | Guerrero Ramiro | +27,258 | - | - |
| 2026-03-31 | Louie Ngar Yee | +33,748 | - | - |
| 2026-03-31 | Luput Cristian | +28,556 | - | - |
| 2026-03-31 | Theagene Jean-Manasse | +27,258 | - | - |
| 2026-03-31 | Smith Stan | +33,099 | - | - |
| 2026-03-31 | CHAOUKI STEVEN M | +27,907 | - | - |
| 2025-12-31 | Theagene Jean-Manasse | +24,060 | - | - |
| 2025-12-31 | Smith Stan | +29,216 | - | - |
| 2025-12-31 | Luput Cristian | +25,206 | - | - |
| 2025-12-31 | Louie Ngar Yee | +29,789 | - | - |
| 2025-12-31 | Guerrero Ramiro | +24,060 | - | - |
| 2025-12-31 | CHAOUKI STEVEN M | +24,633 | - | - |
| 2025-12-22 | Smith Stan | +57,189 | $1.36 | $77,777 |
| 2025-12-22 | Smith Stan | +57,189 | $1.224 | $69,999 |
| 2025-12-22 | Louie Ngar Yee | +81,699 | $1.36 | $111,111 |
| 2025-12-22 | Louie Ngar Yee | +81,699 | $1.224 | $100,000 |
| 2025-12-22 | CHAOUKI STEVEN M | +40,849 | $1.36 | $55,555 |
| 2025-12-22 | CHAOUKI STEVEN M | +40,849 | $1.224 | $49,999 |
| 2025-12-05 | Smith Stan | +4,580 | $1.2 | $5,496 |
| 2025-12-05 | Smith Stan | +4,580 | $1.19 | $5,450 |
| 2025-12-05 | Smith Stan | +4,580 | $1.1997 | $5,495 |
| 2025-11-28 | Vitoc Vlad | +50,000 | $1.1366 | $56,830 |
| 2025-11-28 | Vitoc Vlad | +50,000 | $1.1366 | $56,830 |
| 2025-11-28 | Luput Cristian | +18,145 | $1.1149 | $20,230 |
| 2025-11-26 | Vitoc Vlad | +22,000 | $1.0463 | $23,019 |
| 2025-11-26 | Vitoc Vlad | +22,000 | $1.0463 | $23,019 |
| 2025-11-26 | Luput Cristian | +20,000 | $1.0808 | $21,616 |
| 2025-11-26 | Smith Stan | +15,000 | $1.0388 | $15,582 |
| 2025-11-25 | Vitoc Vlad | +10,500 | $0.9661 | $10,144 |
| 2025-11-25 | Luput Cristian | +10,000 | $0.9785 | $9,785 |
| 2025-11-25 | Vitoc Vlad | +10,500 | $0.9661 | $10,144 |
| 2025-11-25 | Smith Stan | +15,000 | $0.98 | $14,700 |
| 2025-11-24 | Smith Stan | +10,000 | $0.99 | $9,900 |
| 2025-11-24 | Vitoc Vlad | +10,000 | $0.9891 | $9,891 |
| 2025-11-21 | Vitoc Vlad | +1,800 | $0.92 | $1,656 |